Abstract
Despite advancements in treatment, the prognosis for elderly AML patients remains poor. We conducted a retrospective study involving 307 consecutive AML patients, including 71 who underwent haploidentical hematopoietic cell transplantation (Haplo) and 236 who received chemotherapy (Chemo) only. Propensity score matching with 1:1 ratio was performed to balance the groups based on age at treatment initiation, gender, and European Leukemia Net (ELN) 2022 risk classification. 69 case-controlled pairs in the Haplo and Chemo group were analyzed after matching. The two groups were comparable concerning therapy prior to complete remission and 72.5% of patients in the Haplo group received reduced-intensity conditioning. Haplo was associated with a significant survival advantage over Chemo, with a 1-year OS of 77.9% (95% confidence interval(CI), 65.5–86.3, p = 0.001) versus 62.0% (95% CI, 47.9–73.2, p = 0.009). A significanly higher 1-year LFS of 74.1% (95% CI, 61.5–83.1) was also observed compared with 42.0% (95% CI, 29.3–54.0) in the chemotherapy group (p < 0.0001). The survival advantage was majorly due to a significantly reduced relapse incidence (Haplo: 16.5% (95% CI, 8.7–26.5) vs Chemo: 56.6% (95% CI, 42.9–68.2)). The 1-year non-relapse mortality was 9.4% (95% CI, 3.8–18.2) in the Haplo group. To conclude, haploidentical HCT showed superior outcomes to chemotherapy alone and might be recommended to AML patients 55 years or older eligible for transplant in future practice.
Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: Comparative outcomes of chemotherapy versus haplo-HCT.
Fig. 2: Transplant outcomes.
Data availability
Data available on request from the authors.
References
Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32:2541–52. https://doi.org/10.1200/JCO.2014.55.1564.
ArticlePubMedPubMed CentralGoogle Scholar
Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019. EClinicalMedicine. 2024;71:102549 https://doi.org/10.1016/j.eclinm.2024.102549.
ArticlePubMedPubMed CentralGoogle Scholar
Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2:e427–436. https://doi.org/10.1016/S2352-3026(15)00148-9.
ArticlePubMedGoogle Scholar
Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33:4167–75. https://doi.org/10.1200/jco.2015.62.7273.
ArticlePubMedPubMed CentralGoogle Scholar
Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9:118 https://doi.org/10.1186/s13045-016-0347-1.
ArticlePubMedPubMed CentralGoogle Scholar
Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol. 2015;8:84 https://doi.org/10.1186/s13045-015-0182-9.
ArticleCASPubMedPubMed CentralGoogle Scholar
Ye Y, Labopin M, Chen J, Wu D, Gedde-Dahl T Sr, Blaise D, et al. Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT. Blood Cancer J. 2024;14:85 https://doi.org/10.1038/s41408-024-01072-0.
ArticlePubMedPubMed CentralGoogle Scholar
Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46 https://doi.org/10.1186/s13045-020-00882-6.
ArticleCASPubMedPubMed CentralGoogle Scholar
Gorin NC, Labopin M, Blaise D, de Groot M, Socié G, Bourhis JH, et al. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer. 2020;126:1004–15. https://doi.org/10.1002/cncr.32629.
ArticleCASPubMedGoogle Scholar
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617–29. https://doi.org/10.1056/NEJMoa2012971.
ArticleCASPubMedGoogle Scholar
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. https://doi.org/10.1182/blood.2022016867.
ArticleCASPubMedGoogle Scholar
Zimmer M, Kadia T. Approach to the Older Patient with Acute Myeloid Leukemia. Curr Oncol Rep. 2023;25:1203–11. https://doi.org/10.1007/s11912-023-01450-0.
ArticlePubMedGoogle Scholar
Kantarjian H. Acute myeloid leukemia-major progress over four decades and glimpses into the future. Am J Hematol. 2016;91:131–45. https://doi.org/10.1002/ajh.24246.
ArticlePubMedGoogle Scholar
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–5. https://doi.org/10.1182/blood-2005-09-3724.
ArticleCASPubMedPubMed CentralGoogle Scholar
Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94:1127–38. https://doi.org/10.1007/s00277-015-2351-x.
ArticleCASPubMedPubMed CentralGoogle Scholar
Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2:1645–50. https://doi.org/10.1182/bloodadvances.2017015222.
ArticleCASPubMedPubMed CentralGoogle Scholar
Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011;17:1796–803. https://doi.org/10.1016/j.bbmt.2011.06.005.
ArticlePubMedGoogle Scholar
Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33:2599–609. https://doi.org/10.1038/s41375-019-0477-x.
ArticleCASPubMedPubMed CentralGoogle Scholar
Devillier R, Forcade E, Garnier A, Guenounou S, Thepot S, Guillerm G, et al. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2022;6:1804–12. https://doi.org/10.1182/bloodadvances.2021004435.
ArticleCASPubMedPubMed CentralGoogle Scholar
Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, et al. Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study. Clin Cancer Res. 2024;30:1778–87. https://doi.org/10.1158/1078-0432.ccr-23-3673.
ArticlePubMedGoogle Scholar
Ye Y, Labopin M, Gerard S, Yakoub-Agha I, Blau IW, Aljurf M, et al. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024;99:1290–9. https://doi.org/10.1002/ajh.27342.
ArticleCASPubMedGoogle Scholar
Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–64. https://doi.org/10.1182/blood-2017-03-772368.
ArticleCASPubMedPubMed CentralGoogle Scholar
Maffini E, Ngoya M, Galimard JE, Harbi S, Kröger N, Platzbecker U, et al. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023;58:1033–41. https://doi.org/10.1038/s41409-023-02027-y.
ArticleCASPubMedGoogle Scholar
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55 https://doi.org/10.1186/s13045-018-0598-0.
ArticlePubMedPubMed CentralGoogle Scholar
Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, et al. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018;24:1232–6. https://doi.org/10.1016/j.bbmt.2017.09.005.
ArticlePubMedGoogle Scholar
Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, et al. Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone marrow Transplant. 2022;57:911–7. https://doi.org/10.1038/s41409-022-01650-5.
ArticlePubMedPubMed CentralGoogle Scholar
Vo PT, Sandmaier BM, Othus M, Ali N, Rodríguez-Arbolí E, Orvain C et al. Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML. Bone Marrow Transplant. 2025, https://doi.org/10.1038/s41409-025-02516-2.
Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14:145 https://doi.org/10.1186/s13045-021-01159-2.
ArticlePubMedPubMed CentralGoogle Scholar
Download references
Acknowledgements
We would like to express our gratitude to all the patients and personnel involved in this study.
Author information
Author notes
These authors contributed equally: Lin Li, Lixia Zhu.
These authors jointly supervised this work: Yishan Ye, Xi Zhang, He Huang.
Authors and Affiliations
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Lin Li, Lixia Zhu, Mengqi Xiong, Zhile Chen, Yi Luo, Jimin Shi, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Diange Jin, Guanfang Zhang, Shanshan Pei, Yue Liang, Xiujin Ye, Yishan Ye & He Huang
Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
Lin Li, Lixia Zhu, Mengqi Xiong, Zhile Chen, Yi Luo, Jimin Shi, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Diange Jin, Guanfang Zhang, Shanshan Pei, Yue Liang, Xiujin Ye, Yishan Ye & He Huang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China
Ting Chen & Xi Zhang
Authors
Lin Li
View author publications
You can also search for this author inPubMedGoogle Scholar
2. Lixia Zhu
View author publications
You can also search for this author inPubMedGoogle Scholar
3. Mengqi Xiong
View author publications
You can also search for this author inPubMedGoogle Scholar
4. Zhile Chen
View author publications
You can also search for this author inPubMedGoogle Scholar
5. Yi Luo
View author publications
You can also search for this author inPubMedGoogle Scholar
6. Jimin Shi
View author publications
You can also search for this author inPubMedGoogle Scholar
7. Ting Chen
View author publications
You can also search for this author inPubMedGoogle Scholar
8. Yanmin Zhao
View author publications
You can also search for this author inPubMedGoogle Scholar
9. Jian Yu
View author publications
You can also search for this author inPubMedGoogle Scholar
10. Xiaoyu Lai
View author publications
You can also search for this author inPubMedGoogle Scholar
11. Lizhen Liu
View author publications
You can also search for this author inPubMedGoogle Scholar
12. Huarui Fu
View author publications
You can also search for this author inPubMedGoogle Scholar
13. Diange Jin
View author publications
You can also search for this author inPubMedGoogle Scholar
14. Guanfang Zhang
View author publications
You can also search for this author inPubMedGoogle Scholar
15. Shanshan Pei
View author publications
You can also search for this author inPubMedGoogle Scholar
16. Yue Liang
View author publications
You can also search for this author inPubMedGoogle Scholar
17. Xiujin Ye
View author publications
You can also search for this author inPubMedGoogle Scholar
18. Yishan Ye
View author publications
You can also search for this author inPubMedGoogle Scholar
19. Xi Zhang
View author publications
You can also search for this author inPubMedGoogle Scholar
20. He Huang
View author publications
You can also search for this author inPubMedGoogle Scholar
Contributions
He Huang, Xi Zhang and Yishan Ye contributed to the study conception and design. Data collection and analysis were performed by Lin Li, Lixia Zhu, Mengqi Xiong and Zhile Chen. The first draft was written by Lin Li and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Correspondence to Yishan Ye, Xi Zhang or He Huang.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations. Ethical approval was obtained from the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine and Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China. Informed consent was obtained from all participants prior to their involvement in the study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary material
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Li, L., Zhu, L., Xiong, M. et al. Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older. Bone Marrow Transplant (2025). https://doi.org/10.1038/s41409-025-02560-y
Download citation
Received:05 December 2024
Revised:05 March 2025
Accepted:20 March 2025
Published:30 March 2025
DOI:https://doi.org/10.1038/s41409-025-02560-y
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative